Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
/ 678 items
#Healthcare↓
Greenwich LifeSciences Stock Surges on FDA Approval for Breast Cancer Trial
Greenwich LifeSciences (GLSI) shares jump 42% after FDA approves commercial GP2 for Phase III breast cancer prevention trial, reducing regulatory risks ahead of license application.
TD Cowen Downgrades Legend Biotech After Carvykti Sales Miss
TD Cowen cut Legend Biotech to Hold from Buy after weaker Carvykti sales, citing slower demand, safety concerns, and rising competition.
Moderna Surges 69% in 2026 as Cancer Vaccine Shows Five-Year Melanoma Survival Benefits
Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.
Why TransMedics Stock Fell — and Why Analysts Aren’t Worried
TransMedics shares dropped after FDA clearance of a rival liver perfusion system, but TD Cowen says the selloff is overdone and sees no real competitive threat.
Johnson & Johnson Q4 Earnings Beat, But Stock Falls on Stelara
Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.